Literature DB >> 3924540

Cost-containment of antimicrobial therapy.

S L Barriere.   

Abstract

In 1983, health care services for Medicare and Medicaid patients become tied to a diagnosis-related group (DRG) classification and reimbursed based on predetermined rates, regardless of the amounts expended. U.S. hospitals that formerly encouraged resource consumption to generate revenue now urge judicious use of drugs, laboratory tests, and radiology in an effort to contain costs while maintaining quality patient care. Antimicrobials account for the largest proportion of all drugs used in hospitals, but their inappropriate use, unfortunately, is widespread, resulting in poor therapy, emergence of resistance, increased adverse effects, and wasted health care dollars. Newer beta-lactam agents offer enhanced in vitro potency and spectra of activity, improved pharmacokinetic characteristics, and a relative lack of adverse effects. However, these drugs are expensive, and excessive use defeats cost-containment programs necessary under DRG reimbursement. To ensure their appropriate use, a variety of methods and some control system is probably necessary in most hospitals. In certain situations early discharge of hospital patients and home antimicrobial therapy may be the most desirable method to conserve hospital resources and provide quality health care.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924540     DOI: 10.1177/106002808501900405

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  8 in total

1.  Epidemiology and pharmacoeconomic issues relating to acute respiratory tract infections and acute uncomplicated infections of the urinary tract.

Authors:  N M Graham
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

Review 2.  Pharmacoeconomics of antibacterial treatment.

Authors:  P G Davey; M M Malek; S E Parker
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

Review 3.  Methods of minimising the cost of aminoglycoside therapy to hospitals.

Authors:  C A Gentry; K A Rodvold; J S Bertino
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

Review 4.  Antimicrobial therapy. Cost-benefit considerations.

Authors:  B J Guglielmo; G F Brooks
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

5.  Audit of antibiotic usage in medium-sized general hospital over an 11-year period. The impact of antibiotic policies.

Authors:  J C McElnay; M G Scott; J Y Sidara; P Kearney
Journal:  Pharm World Sci       Date:  1995-11-24

6.  Meropenem. A pharmacoeconomic review of its use in serious infections.

Authors:  S M Holliday; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

7.  Assessing antibacterial pharmacoeconomics in the intensive care unit.

Authors:  M C Birmingham; J M Hassett; J J Schentag; J A Paladino
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

8.  Prospective cost analysis of moxalactam versus clindamycin plus gentamicin for endomyometritis after cesarean section.

Authors:  L C Knodel; B R Goldspiel; R S Gibbs
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.